SHANGHAI and TAIPEI, Jan. 7, 2021 /PRNewswire/ — Hongkong Winhealth Pharma Group (Winhealth
Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland
China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB),
bullous
Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland
China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB),
bullous
Neueste Kommentare